|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakajima R, Abe K, Momose M, Fukushima K,
Matsuo Y, Kimura K, Kondo C and Sakai S: Optimization of scan
initiation timing after (11)C-methionine administration for the
diagnosis of suspected recurrent brain tumors. Ann Nucl Med.
31:190–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ostrom QT, Bauchet L, Davis FG, Deltour I,
Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh
KM, et al: The epidemiology of glioma in adults: A ‘state of the
science’ review. Neuro Oncol. 16:896–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Claes A, Idema AJ and Wesseling P: Diffuse
glioma growth: A guerilla war. Acta Neuropathol. 114:443–458. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohgaki H, Dessen P, Jourde B, Horstmann S,
Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM,
Maiorka PC, et al: Genetic pathways to glioblastoma: A
population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeuken JW, Sijben A, Bleeker FE,
Boots-Sprenger SH, Rijntjes J, Gijtenbeek JM, Mueller W and
Wesseling P: The nature and timing of specific copy number changes
in the course of molecular progression in diffuse gliomas: Further
elucidation of their genetic ‘life story’. Brain Pathol.
21:308–320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haynes HR, Camelo-Piragua S and Kurian KM:
Prognostic and predictive biomarkers in adult and pediatric
gliomas: Toward personalized treatment. Front Oncol. 4:472014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Riemenschneider MJ, Jeuken JW, Wesseling P
and Reifenberger G: Molecular diagnostics of gliomas: State of the
art. Acta Neuropathol. 120:567–584. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jenkins RB, Blair H, Ballman KV, Giannini
C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, et al:
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q
and predicts a better prognosis of patients with oligodendroglioma.
Cancer Res. 66:9852–9861. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller CR, Dunham CP, Scheithauer BW and
Perry A: Significance of necrosis in grading of oligodendroglial
neoplasms: A clinicopathologic and genetic study of newly diagnosed
high-grade gliomas. J Clin Oncol. 24:5419–5426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bettegowda C, Agrawal N, Jiao Y, Sausen M,
Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G,
et al: Mutations in CIC and FUBP1 contribute to human
oligodendroglioma. Science. 333:1453–1455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cairncross G, Wang M, Shaw E, Jenkins R,
Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W,
et al: Phase III trial of chemoradiotherapy for anaplastic
oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol.
31:337–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaloshi G, Benouaich-Amiel A, Diakite F,
Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W,
Idbaih A, Paris S, et al: Temozolomide for low-grade gliomas:
Predictive impact of 1p/19q loss on response and outcome.
Neurology. 68:1831–1836. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aldape K, Burger PC and Perry A:
Clinicopathologic aspects of 1p/19q loss and the diagnosis of
oligodendroglioma. Arch Pathol Lab Med. 131:242–251.
2007.PubMed/NCBI
|
|
19
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weller M, Felsberg J, Hartmann C, Berger
H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn
JC, et al: Molecular predictors of progression-free and overall
survival in patients with newly diagnosed glioblastoma: A
prospective translational study of the German Glioma Network. J
Clin Oncol. 27:5743–5750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wick W, Platten M, Meisner C, Felsberg J,
Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M,
et al NOA-08 Study Group of Neuro-oncology Working Group (NOA) of
German Cancer Society, : Temozolomide chemotherapy alone versus
radiotherapy alone for malignant astrocytoma in the elderly: The
NOA-08 randomised, phase 3 trial. Lancet Oncol. 13:707–715. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Stevens MF and Bradshaw TD:
Temozolomide: Mechanisms of action, repair and resistance. Curr Mol
Pharmacol. 5:102–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weller M, Stupp R, Reifenberger G, Brandes
AA, van den Bent MJ, Wick W and Hegi ME: MGMT promoter methylation
in malignant gliomas: Ready for personalized medicine? Nat Rev
Neurol. 6:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Olson RA, Brastianos PK and Palma DA:
Prognostic and predictive value of epigenetic silencing of MGMT in
patients with high grade gliomas: A systematic review and
meta-analysis. J Neurooncol. 105:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van den Bent MJ, Dubbink HJ, Sanson M, van
der Lee Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA,
Taphoorn MJ, Frenay M, et al: MGMT promoter methylation is
prognostic but not predictive for outcome to adjuvant PCV
chemotherapy in anaplastic oligodendroglial tumors: A report from
EORTC Brain Tumor Group Study 26951. J Clin Oncol. 27:5881–5886.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brandes AA, Franceschi E, Tosoni A, Blatt
V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F,
Andreoli A, et al: MGMT promoter methylation status can predict the
incidence and outcome of pseudoprogression after concomitant
radiochemotherapy in newly diagnosed glioblastoma patients. J Clin
Oncol. 26:2192–2197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mellai M, Piazzi A, Caldera V, Monzeglio
O, Cassoni P, Valente G and Schiffer D: IDH1 and IDH2 mutations,
immunohistochemistry and associations in a series of brain tumors.
J Neurooncol. 105:345–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Molenaar RJ, Verbaan D, Lamba S, Zanon C,
Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D,
van Tilborg AA, et al: The combination of IDH1 mutations and MGMT
methylation status predicts survival in glioblastoma better than
either IDH1 or MGMT alone. Neuro-oncol. 16:1263–1273. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wick W, Meisner C, Hentschel B, Platten M,
Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M,
et al: Prognostic or predictive value of MGMT promoter methylation
in gliomas depends on IDH1 mutation. Neurology. 81:1515–1522. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Watanabe T, Nobusawa S, Kleihues P and
Ohgaki H: IDH1 mutations are early events in the development of
astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hartmann C, Meyer J, Balss J, Capper D,
Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et
al: Type and frequency of IDH1 and IDH2 mutations are related to
astrocytic and oligodendroglial differentiation and age: A study of
1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Turcan S, Rohle D, Goenka A, Walsh LA,
Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al: IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan
S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et
al: IDH mutation impairs histone demethylation and results in a
block to cell differentiation. Nature. 483:474–478. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dubbink HJ, Taal W, van Marion R, Kros JM,
van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ,
Gijtenbeek JM, et al: IDH1 mutations in low-grade astrocytomas
predict survival but not response to temozolomide. Neurology.
73:1792–1795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Houillier C, Wang X, Kaloshi G, Mokhtari
K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A,
Laigle-Donadey F, et al: IDH1 or IDH2 mutations predict longer
survival and response to temozolomide in low-grade gliomas.
Neurology. 75:1560–1566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
SongTao Q, Lei Y, Si G, YanQing D, HuiXia
H, XueLin Z, LanXiao W and Fei Y: IDH mutations predict longer
survival and response to temozolomide in secondary glioblastoma.
Cancer Sci. 103:269–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cairncross JG, Wang M, Jenkins RB, Shaw
EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L,
Laperriere NJ, et al: Benefit from procarbazine, lomustine, and
vincristine in oligodendroglial tumors is associated with mutation
of IDH. J Clin Oncol. 32:783–790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rohle D, Popovici-Muller J, Palaskas N,
Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B,
Komisopoulou E, et al: An inhibitor of mutant IDH1 delays growth
and promotes differentiation of glioma cells. Science. 340:626–630.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P
and Gu A: IDH1/IDH2 mutations define the prognosis and molecular
profiles of patients with gliomas: A meta-analysis. PLoS One.
8:e687822013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hamza MA and Gilbert M: Targeted therapy
in gliomas. Curr Oncol Rep. 16:3792014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tandon A and Schiff D: Therapeutic
decision making in patients with newly diagnosed low grade glioma.
Curr Treat Options Oncol. 15:529–538. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weller M, van den Bent M, Hopkins K, Tonn
JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D,
Henriksson R, Balana C, et al European Association for
Neuro-Oncology (EANO) Task Force on Malignant Glioma, : EANO
guideline for the diagnosis and treatment of anaplastic gliomas and
glioblastoma. Lancet Oncol. 15:e395–e403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Muldoon LL, Soussain C, Jahnke K, Johanson
C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM,
et al: Chemotherapy delivery issues in central nervous system
malignancy: A reality check. J Clin Oncol. 25:2295–2305. 2007.
View Article : Google Scholar : PubMed/NCBI
|
